Home › Urothelial (Transitional Cell) Carcinoma › New York
Urothelial (Transitional Cell) Carcinoma clinical trials in New York
29 studies for Urothelial (Transitional Cell) Carcinoma are looking for participants at sites in New York.
Cities in New York
- New York City22 studies
- Queens15 studies
- New Rochelle7 studies
- Staten Island7 studies
- Greenburgh7 studies
- Rochester3 studies
- Syracuse3 studies
- Albany3 studies
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- START New York Long Island LLC, Lake Success
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06270706Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #60, New York
- Exelixis Clinical Site #6, New York
- Exelixis Clinical Site #76, Syracuse
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT05176483A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
- Roswell Park Cancer Institute, Buffalo
- Stony Brook University Medical Center, Stony Brook
- Roswell Park Amherst Center, Williamsville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06524544Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Memorial Sloan Kettering Commack, Commack
- Memorial Sloan Kettering Westchester, Harrison
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- and 3 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT03866382uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
- The Feinstein Institutes for Medical Research, Lake Success
- NYU Grossman School of Medicine, New York
- SUNY Upstate, Syracuse
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT05874921DBC-664 in Adult Patients With Solid Tumors
- START New York, Lake Success
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07705035A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
- Memorial Sloan Kettering Cancer Center ( Site 1031), New York
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05562830Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
- New York Oncology Hematology, Albany
- New York Oncology Hematology, Clifton Park
- Icahn School of Medicine at Mount Sinai, New York
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07421700A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- Columbia University Irving Medical Center, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07277413A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- Weill Cornell Medical College, New York
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07218380Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy
- Mount Sinai Hospital, New York
- NYP/Weill Cornell Medical Center, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT06439836Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
- Memorial Sloan Kettering -Nassau, Commack
- Memorial Sloan Kettering Westchester, Harrison
- Memorial Sloan Kettering Cancer Center, New York
- and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT05239624A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
- Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT07532902GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
- Tisch Cancer Institute (TCI), Icahn School of Medicine, New York
- Columbia University, New York
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT04977453A Study of GEN1106 in Participants With Solid Tumors
- START New York Long Island LLC, Lake Success
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT07416123Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- NYU Langone Hospital - Long Island Investigational Pharmacy, Mineola
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT06293898A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
- University of Rochester Medical Center, Rochester
- Montefiore Medical Center - Bronx, The Bronx
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06774131A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
- START New York Long Island, New Hyde Park
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT07287995Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- New York Cancer & Blood Specialists, New York
- University of Rochester - Wilmot Cancer Institute, Rochester
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 27, 2026 · NCT06582017A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- NYU Langone Health, New York
- Icahn School of Medicine At Mount Sinai Prime, New York
- Clinical Research Alliance, Inc, Westbury
- and 1 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT06330064An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
- Research Site, Albany
- Research Site, New York
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT07720284A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- MSK Commack, Commack
- MSK Wesrchester, Harrison
- Memorial Sloan Kattering Cancer Centre- Investigational Drug Service Pharmacy, Long Island City
- and 6 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT04879329A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 10, 2026 · NCT06695845Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
- Albany MED Health System, Albany
- Integrated Medical Professionals, New York
- Premier Medical Group of the Hudson Valley, P. C., Poughkeepsie
Recruiting
Ages 18 to 88 · All sexes · Updated Jul 2, 2026 · NCT06394869Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
- Start New York, LLC, Lake Success
- MSK, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 18, 2026 · NCT07484022A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma
- Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
- and 1 more
RecruitingObservational study
Ages 18 and older · All sexes · Updated May 29, 2026 · NCT07390617A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer
- Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities), Commack
- Memorial Sloan Kettering West Harrison (All Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 22, 2026 · NCT05562791Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
- Site 02-015 - Associated Medical Professionals of New York, Syracuse
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 24, 2025 · NCT03945162SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Buffalo
- Massive Bio SYNERGY-AI site, Hempstead
- Massive Bio SYNERGY-AI site, Manhasset
- and 2 more
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.